Novo Nordisk A/S (NYSE:NVO) Shares Sold by Marotta Asset Management

Marotta Asset Management lessened its holdings in Novo Nordisk A/S (NYSE:NVO – Free Report) by 3.4% during the fourth quarter, HoldingsChannel.com reports. The fund owned 16,088 shares of the company’s stock after selling 565 shares during the quarter. Marotta Asset Management’s holdings in Novo Nordisk A/S were worth $1,408,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the stock. Novare Capital Management LLC grew its holdings in Novo Nordisk A/S by 3.2% during the 3rd quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock worth $325,000 after acquiring an additional 85 shares in the last quarter. Steel Grove Capital Advisors LLC raised its stake in Novo Nordisk A/S by 2.3% during the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock valued at $541,000 after buying an additional 86 shares in the last quarter. Benjamin Edwards Inc. raised its position in shares of Novo Nordisk A/S by 2.6% during the 2nd quarter. Benjamin Edwards Inc. now owns 3,455 shares of the company’s stock valued at $493,000 after acquiring an additional 87 shares in the last quarter. Rosenberg Matthew Hamilton increased its stake in Novo Nordisk A/S by 2.5% during the third quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company’s stock valued at $454,000 after purchasing an additional 94 shares during the last quarter. Finally, Burns J W & Co. Inc. NY raised its holdings in shares of Novo Nordisk A/S by 1.9% during the third quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company’s stock worth $647,000 after purchasing an additional 100 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 1.3 %

Shares of NYSE NVO traded up $1.15 during mid-day trading on Friday, reaching $86.79. The company had a trading volume of 1,640,341 shares, compared to its average volume of 6,493,137. The stock has a fifty day moving average of $100.86 and a two-hundred day moving average of $119.79. Novo Nordisk A/S has a 12-month low of $81.50 and a 12-month high of $148.15. The company has a market capitalization of $389.47 billion, a price-to-earnings ratio of 28.09, a PEG ratio of 1.37 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of analyst reports. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $140.20.

Read Our Latest Stock Analysis on NVO

Novo Nordisk A/S Company Profile

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Featured Stories

• Five stocks we like better than Novo Nordisk A/S
• Best Aerospace Stocks Investing
• With This Kind of Data, The Fed Isn’t Cutting Rates This Year
• Why Are These Companies Considered Blue Chips?
• 3 EV Stocks Offering Unique Alternatives to Tesla
• Insider Trading – What You Need to Know
• 3 Stocks Leveraging NVIDIA’s Strength for Profits

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).